Compare EE & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EE | SPTX |
|---|---|---|
| Founded | 2003 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2022 | 2026 |
| Metric | EE | SPTX |
|---|---|---|
| Price | $32.13 | $18.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $43.46 | $38.29 |
| AVG Volume (30 Days) | ★ 387.7K | 155.6K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | ★ 0.79 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $1,228,263,000.00 | N/A |
| Revenue This Year | $24.05 | N/A |
| Revenue Next Year | $27.03 | N/A |
| P/E Ratio | $43.27 | ★ N/A |
| Revenue Growth | ★ 44.26 | N/A |
| 52 Week Low | $24.89 | $17.59 |
| 52 Week High | $43.18 | $28.38 |
| Indicator | EE | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.09 | 44.86 |
| Support Level | $32.03 | $18.72 |
| Resistance Level | $36.04 | $22.75 |
| Average True Range (ATR) | 1.34 | 1.81 |
| MACD | -0.44 | -0.26 |
| Stochastic Oscillator | 7.59 | 32.71 |
Excelerate Energy Inc. offers comprehensive LNG solutions by providing integrated services throughout the LNG value chain. The company delivers a full range of regasification services, including Floating Storage and Regasification Units (FSRUs), infrastructure development, and the supply of LNG and natural gas. With operational presence in several countries - Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States. The company generates revenue through Terminal Services, as well as from LNG, gas, and power. These revenues are derived from its vertically integrated activities in LNG sourcing, transportation, regasification, and power generation.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.